Join ANCOR Diamond Partner Jazz Pharmaceuticals on May 20 for this important presentation on Health Care Resource Utilization (HCRU) Before and After the Initiation of Cannabidiol Among Commercial and Medicaid Patients with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), Tuberous Sclerosis Complex (TSC) and other Refractory Epilepsies.
Presentation objectives:
Discuss HCRU and Medical costs before and after Epidiolex® (cannabidiol) initiation
Review anti-seizure medicine and anxiolytic medication use before and after Epidiolex® (cannabidiol) initiation
Presenter
Michael Faithe, Director, Payer Value & Outcomes, Jazz Pharmaceuticals
Stay Informed on the Latest Research & Analysis from ANCOR